Home › Parathyroid Cancer › NCT05997810

Parathyroid Tumor Clonal Status

A Phase 2 Biomarker Study of Parathyroid Tumor Clonal Status in Hyperparathyroid Disorders (Primary, Secondary, and Tertiary)

Who can join

Ages 18 to 80 · Women · Healthy volunteers welcome

Inclusion Criteria:

* 1\. Diagnosed with hyperparathyroidism (primary, secondary, or tertiary), biochemically confirmed (e.g., serum calcium and/or intact PTH consistent with the underlying etiology), and undergoing clinically indicated management
* Female and male patients
* Age ≥ 18 years
* Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

Exclusion Criteria:

* Patients with a history of cervicofacial irradiation.
* Patients currently taking lithium or with a history of lithium use.
* Pregnant patients

About the study

To define the frequency of monoclonal-X and polyclonal-X tumors in hyperparathyroid disorders patients having PTX and to define the relationship between parathyroid tumor clonal status and multiple gland neoplasia (MGN), we will compare surgical and pathologic outcomes to tumor clonal status in a multicenter cohort of patients having bilateral neck exploration (BNE) and PTX (primary objectives).

Sponsor: Washington University School of Medicine · Participants: 839 · Started: Jul 28, 2023

Contact the study team

• John A Olson, MD · Phone: (314) 362-8020
• Kathleen Harris · Phone: (314) 273-1433

Official record on ClinicalTrials.gov — NCT05997810

Locations in the U.S.

Conditions

• Parathyroid Cancer
• Primary Hyperparathyroidism

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.